All News
Filter News
Found 808,165 articles
-
TransMedics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
8/28/2023
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX) today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference at the Sheraton New York.
-
QuidelOrtho to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
8/28/2023
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023.
-
Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
8/28/2023
Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that management will be presenting virtually at the H.C. Wainwright 25th Annual Global Investment Conference.
-
EDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE
8/28/2023
Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023.
-
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
8/28/2023
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET.
-
T2 Biosystems Praises CDC’s Actions Aimed at Optimizing U.S. Hospital Sepsis Programs The U.S. Centers for Disease Control and Prevention Releases 2023 Hospital Sepsis Program Core Elements
8/28/2023
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today praised actions taken by the U.S. Centers for Disease Control and Prevention (CDC) aimed at optimizing hospital sepsis programs in the United States.
-
Paragon 28 to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
8/28/2023
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 4:55 p.m. Eastern Time / 2:55 p.m. Mountain Time.
-
NurExone Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/28/2023
NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, is pleased to announce the filings of its financial results for the quarter ended June 30, 2023 and provide a corporate update.
-
CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine
8/28/2023
CSL Seqirus, a business of CSL (ASX: CSL), was selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to deliver one bulk lot of H5N8 A/Astrakhan antigen to the U.S. government.
-
Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
8/28/2023
Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) today announced that its Founder, Chairman, and CEO Quang Pham; CFO Matthew Szot; and CMO, Dr. Douglas Losordo, will be participating in the H.C. Wainwright 25th Annual Global Investment Conference.
-
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 2023 Healthcare Conference
8/28/2023
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during Wells Fargo’s 2023 Healthcare Conference on Thursday, September 7 at 11:00 AM Eastern Time (8:00 AM Pacific Time).
-
Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
8/28/2023
Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, September 11th through Wednesday, September 13th starting at 7:00 a.m. ET.
-
EmVenio Research expands clinical research team to streamline efficiency and compliance processes
8/28/2023
EmVenio Research recently appointed Christine Scheuring and Vickie Leathers to manage clinical research teams and processes.
-
ADVENT Study of the FARAPULSE™ Pulsed Field Ablation System Meets Primary Efficacy and Safety Endpoints
8/27/2023
Boston Scientific Corporation announced positive 12-month results from the pivotal ADVENT clinical trial of the FARAPULSE™ Pulsed Field Ablation System*, a nonthermal treatment in which electric fields selectively ablate heart tissue in patients with atrial fibrillation.
-
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
8/27/2023
BridgeBio Pharma, Inc. announced the presentation of detailed positive results from its Phase 3 ATTRibute-CM study of acoramidis for patients with ATTR-CM by Julian Gillmore, MBBS, M.D., Ph.D., FRCP, FRCPath, in a Hot Line session at the European Society of Cardiology Congress 2023.
-
Specialised Therapeutics acquires commercialisation rights to new oral MND therapy
8/27/2023
Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd will partner with Netherlands based biotechnology company Treeway BV to commercialise a new therapy to treat Amyotrophic Lateral Sclerosis – the most common form of Motor Neurone Disease - in Australia and New Zealand.
-
American Regent Announces Results From Phase 3 HEART-FID Trial with INJECTAFER®
8/26/2023
American Regent, Inc., a Daiichi Sankyo Group company, announced results from the phase 3 HEART-FID trial of INJECTAFER® for the treatment of iron deficiency in adult heart failure patients with reduced ejection fraction.
-
Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
8/26/2023
Amgen announced data from the final analysis of the Phase 2 OCEAN-DOSE study of olpasiran, a small interfering RNA during the Late-Breaking Science Session at the European Society of Cardiology Annual Meeting being held in Amsterdam.
-
While an initial analysis showed improvements in progression-free survival and objective response rate, a second analysis saw no improvement in overall survival.
-
A second trial shows Novo Nordisk’s Wegovy improves heart health. Meanwhile, many other drugs are beginning to face generic competition, including from newly approved biosimilars.